PACB
Pacific Biosciences of California
NASDAQ: PACB · HEALTHCARE · MEDICAL DEVICES
$1.59
+8.16% today
Updated 2026-04-30
Market cap
$493.67M
P/E ratio
—
P/S ratio
3.09x
EPS (TTM)
$-1.82
Dividend yield
—
52W range
$1 – $3
Volume
5.8M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+5.0
Quality
C+2.5
Profitability
F6.0
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$2.38
+49.37%
12-Month target
—
—
Intrinsic (DCF)
$2.21
Margin of safety
+16.74%
0 Strong Buy4 Buy3 Hold0 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 13.80% QoQ
+ 16.74% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-24.93M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $128.30M | $200.52M | $154.01M | $160.00M | $160.00M |
| Net income | $-314.25M | $-306.74M | $-309.85M | $-546.38M | $-40.37M |
| EPS | — | — | — | — | $-1.82 |
| Free cash flow | $-280.14M | $-275.39M | $-212.25M | $-113.92M | $-24.93M |
| Profit margin | -244.92% | -152.97% | -201.18% | -341.47% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-08 | GIBSON, CHRISTOPHER | Buy | 77,842 | — |
| 2026-04-08 | GIBSON, CHRISTOPHER | Buy | 57,473 | — |
| 2026-04-01 | GIBSON, JAMES R II | Sale | 88,185 | $1.37 |
Peer comparison
Smart narrative
Pacific Biosciences of California trades at $1.59. Our Smart Value Score of 30/100 indicates the stock is weak. TTM revenue stands at $160.00M. Our DCF model estimates intrinsic value at $2.21.
Frequently asked questions
What is Pacific Biosciences of California's stock price?
Pacific Biosciences of California (PACB) trades at $1.59.
Is Pacific Biosciences of California overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell). DCF value $2.21.
What is the price target of Pacific Biosciences of California (PACB)?
The analyst target price is $2.38, representing +49.4% upside from the current price of $1.59.
What is the intrinsic value of Pacific Biosciences of California (PACB)?
Based on our DCF model, intrinsic value is $2.21, a +16.7% margin of safety versus $1.59.
What is Pacific Biosciences of California's revenue?
TTM revenue is $160.00M.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.09x
ROE-213.50%
Beta2.33
50D MA$1.49
200D MA$1.68
Shares out0.31B
Float0.29B
Short ratio—
Avg volume5.8M
Performance
1 week-7.02%
1 month+26.19%
3 months-33.19%
YTD-14.97%
1 year—
3 years—
5 years—